Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.
about
Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11The renin-angiotensin system and the heart: a historical reviewPotential role of dipeptidyl peptidase IV in the pathophysiology of heart failureRapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overloadBNP and Heart Failure: Preclinical and Clinical Trial Data.A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions.Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD).Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.Paradoxes of body fluid volume regulation in health and disease. A unifying hypothesis.Neuroendocrine activity in untreated heart failureNeurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failureEvidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failureGuanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.The natriuretic peptides: physiology and role in left-ventricular dysfunction.Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathyAugmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heartClearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog.Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.Role of endogenous atrial natriuretic factor in acute congestive heart failure.Water and sodium regulation in heart failure.Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applicationsAcute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man.Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure.Synthesis of atrial natriuretic polypeptide in human failing hearts. Evidence for altered processing of atrial natriuretic polypeptide precursor and augmented synthesis of beta-human ANP.Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.ANP-induced signaling cascade and its implications in renal pathophysiologyA novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertensionOutpatient management of congestive heart failureNesiritide for the treatment of congestive heart failure.Human B-type natriuretic peptide is not degraded by meprin A.Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications.
P2860
Q24552201-836FB7B2-9A2E-45D9-BB77-5157F7F17EC7Q24563079-EC7D7558-87E1-4E27-8EC3-2D7897EC14E0Q26829634-F13FE954-D842-43FB-8364-FE647BC8906DQ28568167-19E06106-1D2F-4BA0-9096-771A10DA490DQ30909922-BD113AAD-2952-4197-9934-7F20D2C0926DQ33577067-BF4B92B5-22B4-48E1-97AC-D68F0F8A5ED2Q33588264-4801F91A-C56B-4C50-A3BD-22EBDE1F4EBFQ33604698-8B2A14BB-60B0-450F-A224-17611ABE2094Q33608122-F4B3A73D-5B2C-472E-8514-27107D86784BQ33611263-B752A4ED-B540-4BC4-8B3F-4E17D06EEC8FQ33614319-BF2EE5EA-B390-4F36-9C8E-2094FE492360Q33614402-043730D5-249F-4F4D-806B-A35FB61A1274Q33639278-E8F6A662-460F-4749-A378-04EDFCAB7DD4Q33756693-BDF98FFE-975C-45D7-A5B5-CAA48D5D3928Q33792340-679A1610-D50F-4FFE-9797-484A48EFA373Q34171357-A1969323-1D98-47C2-B457-0D5FD4745497Q34184637-6382A528-5318-4722-8401-2B0CE69F75F5Q34207430-6FC3FA66-C4FC-419D-8CDA-577646BD50FFQ34209627-AE803C02-6476-4ACE-B623-955274F55716Q34308742-9BABC9FD-B47C-48D6-BCDD-5417B8B59832Q34448373-C8E88DA9-E111-464A-B985-67AB46F2B06AQ34496097-D4B0FC33-726B-4048-B67D-42F3C63418BAQ34563544-AFC0020D-8153-40F0-B12D-E1A1146FC1A9Q34564865-D5A27130-4C1B-4F81-8FD2-97CAFC47E34CQ34566859-280709CC-AABA-4170-9E0C-32A169FC77F4Q34568884-4085752F-8E7C-4419-AF9D-752151A1660AQ34581546-1B1AC70A-2481-488C-AF15-FCB414AB9774Q34584706-E49D00D8-DC27-40F5-86F0-AAD488F84E72Q34906050-F34275EA-B44C-4B59-8764-ABC5BCEE8C62Q35200873-A2539885-EAD7-4E1E-A82D-335F31C6AB1DQ35579032-27F3061F-F06D-470E-8584-C630F4CADAC1Q35580130-1AFB060F-56AB-4D99-995D-9F2F34F9CCA8Q35590430-17E34194-49FD-454C-B893-A91B77A8674CQ35598979-F68A0F5A-9AC5-445F-87A8-9CE800D4B0EEQ35622455-3A5E0A2E-26F9-4244-9657-985BB8274D83Q35659994-4A550039-D2A3-4007-82A9-1B39FC7CDBE6Q35665407-F422BEC8-B1BF-4187-81B3-E46577BF3A1AQ35753426-FB3DA3AC-9A56-4649-8AA2-0F759B9DD258Q35831456-D7CC5113-A634-4237-A479-9E42F4C2E4C3Q36350919-4CB4CDC1-09B8-468B-95AB-2632A693626B
P2860
Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Atrial natriuretic factor in n ...... responses to peptide infusion.
@en
type
label
Atrial natriuretic factor in n ...... responses to peptide infusion.
@en
prefLabel
Atrial natriuretic factor in n ...... responses to peptide infusion.
@en
P2093
P2860
P921
P356
P1476
Atrial natriuretic factor in n ...... responses to peptide infusion.
@en
P2093
A Shaknovich
J H Laragh
K Pondolfino
M J Camargo
P2860
P304
P356
10.1172/JCI112723
P407
P577
1986-11-01T00:00:00Z